Citrini explored single molecule for five toxins despite Claude failure warning

Citrini Therapeutics explored a single molecule to bind five toxins, despite Claude cautioning the approach was very likely to fail, according to Oct. 20, 2026 material. I see the value here as early negative screening: killing weak designs before expensive lab work saves time and capital.